Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells

@article{Fusi2007VascularAO,
  title={Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cells},
  author={Fabio Fusi and Antonella Ferrara and Attila Zalatnai and Joseph Andrew Molnar and Giampietro Sgaragli and Simona Saponara},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2007},
  volume={61},
  pages={443-451}
}
The aim of this study was to investigate the effects of two novel multidrug-resistance reverting agents, ALIS 409 [1,3-dimethyl-1,3-p-fluorophenyl-1,3(3-morfolinopropyl)-1,3-disiloxan dihydrochloride] and ALIS 421 {1,3-dimethyl-1,3-(4-fluorophenyl)-1,3[3(4-buthyl)-(1-piperazinyl)-propyl]-1,3-disiloxan tetrahydrochloride}, on vascular functions in vitro. A comparison of their mechanical and electrophysiological actions in rat aorta rings and single rat tail artery myocytes, respectively, was… CONTINUE READING